Enhanced-GeneSight Psychotropic (E-GEN)

GENETIC2 trials

Sponsors

Assurex Health Inc., St. Joseph's Healthcare Hamilton

Conditions

DepressionDepressive DisorderDepressive Disorder, MajorSchizoaffective DisorderSchizophrenia

Phase 4

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

CompletedNCT02466477

Assurex Health Inc.Depression, Depressive Disorder, Depressive Disorder, Major

Start: 2015-06-30End: 2019-09-30Updated: 2020-04-30

Unknown Phase

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics

CompletedNCT02573168

St. Joseph's Healthcare HamiltonSchizoaffective Disorder, Schizophrenia

Start: 2016-01-31End: 2020-09-30Updated: 2020-11-19

Related Papers

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.

2022-03-1430 citations

Study protocol for the antidepressant advisor (ADeSS): a decision support system for antidepressant treatment for depression in UK primary care: a feasibility study

BMJ Open2020-05-0116 citations